{"id":"NCT02954172","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","briefTitle":"Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC","officialTitle":"Study to Evaluate the Efficacy and Safety of IBI305 in Combination With Paclitaxel/Carboplatin Versus Bevacizumab in Combination With Paclitaxel/Carboplatin in Treatment-na√Øve Patients With Advanced or Recurrent Non-squamous NSCLC","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11-28","primaryCompletion":"2018-10-19","completion":"2019-11-12","firstPosted":"2016-11-03","resultsPosted":"2020-12-08","lastUpdate":"2020-12-08"},"enrollment":450,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["NSCLC"],"interventions":[{"type":"DRUG","name":"Bevacizumab in Combination With Paclitaxel/Carboplatin","otherNames":["Avastin"]},{"type":"DRUG","name":"IBI305 in Combination with Paclitaxel/Carboplatin","otherNames":["Bevacizumab Biosimilar"]}],"arms":[{"label":"Bevacizumab in Combination With Paclitaxel/Carboplatin","type":"EXPERIMENTAL"},{"label":"IBI305 in Combination with Paclitaxel/Carboplatin","type":"ACTIVE_COMPARATOR"}],"summary":"A randomized, double blind, multicenter phase3 study .","primaryOutcome":{"measure":"Objective Response Rate","timeFrame":"18 weeks","effectByArm":[{"arm":"Bevacizumab in Combination With Paclitaxel/Carboplatin","deltaMin":46.4,"sd":null},{"arm":"IBI305 in Combination With Paclitaxel/Carboplatin","deltaMin":44.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":["32010577"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":85,"n":226},"commonTop":["White blood cell count decreased","Neutrophil count decreased","Platelet count decreased","Anaemia","Constipation"]}}